Can I Take Vitamin B12 with Farxiga (Dapagliflozin)?

The Short Answer: No Interaction Between Dapagliflozin and Vitamin B12

Dapagliflozin and vitamin B12 do not interact. The drug works by blocking the sodium-glucose cotransporter 2 (SGLT2) protein in the proximal tubule of the kidney, causing excess glucose to spill into the urine. Vitamin B12 absorption depends on intrinsic factor in the gut and, for high oral doses, passive diffusion across the intestinal wall. These two pathways share no overlapping mechanism.

The FDA prescribing information for Farxiga lists no interaction with vitamin supplements of any kind. No peer-reviewed pharmacokinetic study has identified a meaningful change in dapagliflozin area-under-the-curve (AUC) or B12 serum concentrations when both are used together.

Why the Question Still Matters

Despite the clean interaction profile, the question is clinically meaningful for one specific reason: many patients with type 2 diabetes take Farxiga alongside metformin, and metformin is a well-documented depleter of vitamin B12. Sorting out which drug, if any, is responsible for a patient's falling B12 level matters enormously for management decisions.

Dapagliflozin's Mechanism at a Glance

Dapagliflozin inhibits SGLT2 with a half-maximal inhibitory concentration (IC50) of approximately 1.1 nM and is metabolized primarily by UGT1A9 in the liver and kidney to an inactive glucuronide metabolite [1]. It does not induce or inhibit CYP450 enzymes to any clinically relevant degree, so it cannot alter the absorption, distribution, or elimination of B12.

How Metformin Depletes Vitamin B12 (and Why This Gets Blamed on Farxiga)

This is where confusion most often arises. Metformin, not dapagliflozin, is the drug that reduces B12 absorption.

The mechanism is now well characterized. Metformin interferes with calcium-dependent membrane action in the terminal ileum, the segment of the small intestine where the intrinsic factor-B12 complex binds to cubilin receptors [2]. By disrupting this calcium-dependent step, metformin reduces the efficiency of B12 uptake by 15-30% in susceptible patients.

Prevalence Data

A cross-sectional analysis published in the BMJ (N=155, followed for up to 4.3 years) found that 22% of metformin-treated patients had deficient B12 levels (<150 pmol/L) compared with 10% of controls not on metformin [3]. A larger community-based observational study placed the prevalence of biochemical B12 deficiency among long-term metformin users as high as 30%, particularly in patients taking doses above 1,500 mg/day for more than 4 years [4].

Why Patients Think Farxiga Is Involved

When a patient starts Farxiga as an add-on to established metformin therapy and then develops tingling or fatigue, the newer drug gets the blame. The timeline feels intuitive but is pharmacologically misleading. Farxiga has no ileal receptor interaction and exerts no effect on intrinsic factor or cubilin. The depletion was already occurring before Farxiga was added.

The Clinical Consequence: Neuropathy That Looks Like Diabetic Neuropathy

B12 deficiency causes a demyelinating peripheral neuropathy that is clinically indistinguishable from diabetic peripheral neuropathy. Both produce distal symmetric tingling, burning, and numbness. A 2010 Diabetes Care study (N=1,900, the DPPOS cohort) found that metformin use was independently associated with a lower serum B12 and higher rates of peripheral neuropathy even after adjusting for HbA1c [5]. Patients being worked up for worsening neuropathy while on dapagliflozin-plus-metformin should have serum B12 checked before attributing symptoms to blood glucose alone.

Is Vitamin B12 Safe to Take with Farxiga?

Yes. B12 is a water-soluble vitamin with an extremely wide safety margin. The Institute of Medicine set no tolerable upper intake level for B12 because no adverse effects from high oral or intramuscular doses have been documented in the general population [6].

Pharmacokinetic Independence

Oral cyanocobalamin at doses of 500-2,000 mcg is absorbed largely by passive diffusion at high concentrations, bypassing the intrinsic factor pathway entirely. This passive route is not touched by dapagliflozin's renal glucose-spilling mechanism. Taking both agents together, at any time of day, does not alter the pharmacokinetics of either compound.

Specific Patient Populations to Watch

Patients on triple therapy (metformin + dapagliflozin + a proton pump inhibitor). Proton pump inhibitors (PPIs) independently reduce B12 absorption by impairing the acid-mediated release of protein-bound B12 from food [7]. A patient on all three compounds faces two separate absorption insults: metformin at the ileal cubilin receptor and PPIs at the gastric acid step. Supplementing with high-dose oral cyanocobalamin or switching to sublingual or intramuscular forms may be more effective in this group.

Patients with CKD. Farxiga carries an FDA indication for CKD (eGFR 25-75 mL/min/1.73 m²). Advanced CKD alters B12 distribution and can raise or lower measured serum B12 in ways that do not accurately reflect tissue stores. Methylmalonic acid (MMA) and homocysteine are more reliable functional markers of B12 adequacy in CKD patients [8].

Older adults. Adults over 65 absorb crystalline B12 from supplements reliably but absorb food-bound B12 poorly because of achlorhydria. Supplementation is often appropriate independent of any medication use.

Monitoring: When and How Often to Check B12

The 2025 American Diabetes Association (ADA) Standards of Medical Care in Diabetes state: "Vitamin B12 deficiency should be considered in metformin-treated patients, especially those with anemia or peripheral neuropathy, and periodic measurement of vitamin B12 levels should be considered in these patients." [9]

The HealthRX clinical team applies the following monitoring schedule for patients on dapagliflozin:

Monitoring Schedule by Medication Combination

Dapagliflozin alone (no metformin). No routine B12 monitoring is indicated by current evidence. Check only if the patient develops neurological symptoms or macrocytic anemia.

Dapagliflozin plus metformin, metformin dose <1,000 mg/day, treatment duration <2 years. Baseline serum B12 at initiation of metformin, then every 2 years.

Dapagliflozin plus metformin, dose >1,500 mg/day or treatment >4 years. Annual serum B12. Add MMA if serum B12 falls into the indeterminate range of 150-300 pmol/L.

Any patient with peripheral neuropathy symptoms. Check serum B12, MMA, and homocysteine regardless of which drugs are in the regimen. Do not wait for the scheduled interval.

Interpreting the Results

A serum B12 below 148 pmol/L (200 pg/mL) is generally considered deficient. The 148-300 pmol/L zone is indeterminate. An MMA above 0.4 micromol/L in that indeterminate range confirms functional deficiency even when the serum level appears borderline [10].

Macrocytic anemia (mean corpuscular volume above 100 fL) alongside a low-normal B12 strongly supports supplementation. Neuropathy without anemia occurs in approximately 25% of B12-deficient patients, so a normal complete blood count does not rule out the diagnosis [11].

How to Supplement B12 if You Are on Farxiga and Metformin

Oral Cyanocobalamin: The First-Line Option

For mild-to-moderate deficiency in patients who can absorb high-dose oral B12, 1,000 mcg of oral cyanocobalamin daily is the most common starting point. At this dose, approximately 1% is absorbed by passive diffusion even in the absence of functional intrinsic factor. A 2018 Cochrane review found that high-dose oral B12 (1,000-2,000 mcg/day) was as effective as intramuscular injections for correcting deficiency in most patients [12].

Intramuscular Cyanocobalamin or Hydroxocobalamin

When the patient has severe neurological symptoms, very low serum B12 (<100 pmol/L), or confirmed malabsorption, intramuscular injection is preferred for speed. A typical loading regimen is 1,000 mcg IM daily for 7 days, then weekly for 4 weeks, then monthly for maintenance. In the UK, hydroxocobalamin is preferred over cyanocobalamin IM because of its longer tissue retention [13].

Sublingual Methylcobalamin

Sublingual B12 bypasses gastrointestinal absorption entirely through buccal mucosa. It is a reasonable alternative for patients who object to injections or have documented intrinsic factor antibodies. Evidence comparing sublingual to IM is limited but generally favorable for achieving adequate serum levels [14].

Timing Relative to Dapagliflozin

No dose-separation window is required. Dapagliflozin is typically taken in the morning with or without food, and B12 can be taken at the same time or at any other time without any concern for mutual interference.

What the DECLARE-TIMI 58 Trial Tells Us (And Does Not Tell Us)

DECLARE-TIMI 58 (N=17,160) was the cardiovascular outcomes trial that supported Farxiga's cardiovascular and renal labels. The trial ran for a median of 4.2 years and enrolled patients on background antidiabetic therapy, including metformin in approximately 82% of participants [15].

DECLARE-TIMI 58 did not measure B12 levels or neuropathy endpoints as pre-specified outcomes, so it cannot directly answer B12-related questions. However, the trial's large sample and long duration confirm that dapagliflozin itself produced no new signals for neuropathy beyond what was expected from the underlying diabetes. Neuropathy signals in that population remain attributable to hyperglycemia and, in metformin users, potentially to B12 depletion, not to dapagliflozin.

The DAPA-CKD trial (N=4,304), which studied dapagliflozin in chronic kidney disease patients with and without diabetes, also did not identify any B12-related adverse event signal over a median follow-up of 2.4 years [16].

What Clinicians Say

The American Diabetes Association 2025 Standards of Care note explicitly that "long-term use of metformin is associated with vitamin B12 deficiency" and recommend periodic B12 measurement in at-risk patients [9]. The guidance applies to any patient whose regimen includes metformin, regardless of what other antidiabetic agents are co-prescribed.

A practical framing from clinical pharmacology: dapagliflozin is a renal glucose transporter blocker. Vitamin B12 is a water-soluble micronutrient absorbed in the gut and stored in the liver. These two agents operate in entirely separate anatomical compartments with no shared protein targets, enzymes, or transporters. The absence of an interaction is mechanistically expected, not merely empirical.

Practical Checklist Before Adding B12 to a Farxiga Regimen

Running through these five points takes less than two minutes at a telehealth visit.

1. Is the patient also on metformin? If yes, B12 monitoring becomes relevant.
2. What is the metformin dose and how long has the patient been on it? Higher doses (>1,500 mg/day) and longer duration (>4 years) raise risk.
3. Does the patient have any neurological symptoms (tingling, numbness, balance issues) or unexplained fatigue? Order serum B12, MMA, and a complete blood count now.
4. Is the patient also on a PPI? Add this as a compounding absorption risk factor.
5. Does the patient have CKD? Use MMA and homocysteine rather than serum B12 alone for the most accurate functional assessment.

Supplementing with 1,000 mcg oral cyanocobalamin daily is low-cost, very low-risk, and appropriate for most patients who check boxes 1 and 2 above, even while awaiting lab confirmation.

Drug Interactions Dapagliflozin Actually Has (For Context)

Understanding what Farxiga genuinely interacts with helps clarify why B12 is not on the list.

Dapagliflozin's real interaction concerns include: insulin and insulin secretagogues (sulfonylureas), which can potentiate hypoglycemia when added to dapagliflozin-driven glucosuria; diuretics, which add to volume depletion risk; and lithium, where dapagliflozin-driven natriuresis may reduce lithium clearance and raise lithium levels [1]. None of these mechanisms apply to vitamin B12.

Loop diuretics and thiazides combined with dapagliflozin warrant closer blood pressure and electrolyte monitoring. Vitamin supplements, including B12, B6, folate, vitamin D, and magnesium, have no pharmacokinetic interaction with SGLT2 inhibitors in published literature.

Summary Data Table: Dapagliflozin and Vitamin B12 Side-by-Side

| Feature | Dapagliflozin (Farxiga) | Vitamin B12 (Cyanocobalamin) | |---|---|---| | Mechanism | SGLT2 inhibition, renal tubule | Cofactor for methionine synthase and methylmalonyl-CoA mutase | | Primary absorption site | Oral, GI tract, then renal action | Ileum (IF-dependent) or passive diffusion (high dose) | | Primary metabolism | UGT1A9 glucuronidation | Stored in liver; minimal metabolism | | Affected by the other? | No | No | | Dose separation needed | N/A | No | | Monitoring needed | eGFR, HbA1c, blood pressure | Serum B12, MMA if borderline |